Sai Teja Drugs And Intermidiates Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 29-10-2024
- Paid Up Capital ₹ 2.00 Cr
as on 29-10-2024
- Company Age 24 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.50 Cr
as on 29-10-2024
- Satisfied Charges ₹ 3.86 Cr
as on 29-10-2024
- Revenue 9.92%
(FY 2023)
- Profit -177.96%
(FY 2023)
- Ebitda -219.06%
(FY 2023)
- Net Worth -9.97%
(FY 2023)
- Total Assets 9.49%
(FY 2023)
About Sai Teja Drugs And Intermidiates
The Corporate was formerly known as Sgvs Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹8.50 Cr. The company has closed loans amounting to ₹3.86 Cr, as per Ministry of Corporate Affairs (MCA) records.
Chandrasekhara Kallam, Bhargav Kallam, and Latha Kallam serve as directors at the Company.
- CIN/LLPIN
U24239TG2000PTC035154
- Company No.
035154
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Aug 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Sai Teja Drugs And Intermidiates?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chandrasekhara Kallam  | Director | 07-Mar-2007 | Current |
| Bhargav Kallam | Director | 27-Dec-2010 | Current |
| Latha Kallam | Director | 15-Jan-2011 | Current |
Financial Performance and Corporate Structure Insights of Sai Teja Drugs And Intermidiates.
Sai Teja Drugs And Intermidiates Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 9.92% increase. The company also saw a substantial fall in profitability, with a 177.96% decrease in profit. The company's net worth dipped by a decrease of 9.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sai Teja Drugs And Intermidiates?
Unlock access to Sai Teja Drugs And Intermidiates's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Shree Vinayaka Life Sciences Private LimitedActive 20 years 11 daysChandrasekhara Kallam, Bhargav Kallam and 1 more are mutual person
- Sri Durga Skyways Private LimitedInactive For E-Filing 9 months 2 days
Chandrasekhara Kallam is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 15 Nov 2012 | ₹8.50 Cr | Open |
Andhra Pradesh State Financial Corporation Creation Date: 26 Mar 2009 | ₹3.06 Cr | Satisfied |
Lord Krishna Bank Ltd Creation Date: 29 Apr 2004 | ₹5.00 M | Satisfied |
How Many Employees Work at Sai Teja Drugs And Intermidiates?
Sai Teja Drugs And Intermidiates has a workforce of 17 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sai Teja Drugs And Intermidiates, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai Teja Drugs And Intermidiates's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
